ArtemiC histology on rats confirm no pathological impact
Filed with ASX · · 4 pages · English
Earlier from Argent Biopharma
- First high THC products shipped direct to Brazil patients
- MGC pharma launches CannEpil app
- Update on ArtemiC phase II trial on COVID-19 patients
- Mxc welcomes new FCA guidance for cannabis sector in the UK
- Mxc well positioned for tga down-schedule of cbd products
Later from Argent Biopharma
- Mgc pharma delivers record consecutive weekly sales growth
- September Quarterly Activity and Cashflow Report
- Completion of phase II clinical trial on COVID-19 patients
- Further successful results from glioblastoma research
- MGC pharma completes acquisition of telehealth platform MCC
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma